Drugs / HRS-1167
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06719973 | May 2025 | cancer | EMD Serono Research & Development Institute, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT06509906 | Oct 2024 → Dec 2025 | neoplasm | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT06421935 | Aug 2024 → Feb 2027 expected | neoplasm | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06198556 | Jan → Feb 2024 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05473624 | Aug 2022 → Dec 2026 expected | cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06689163 | Dec 2024 → Nov 2025 overdue | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06568094 | Sep 2024 → Jun 2026 overdue | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06308406 | Mar 2024 → Oct 2025 | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06516289 | Sep 2024 → Jun 2026 overdue | Her2-receptor negative breast cancer | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-1167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05473624 ↗ |
| Known as | M9466 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06509906 ↗ |
| Action | Inhibit | “PARP1 Inhibitor M9466” NCT06421935 ↗ |
| Route | Oral | “single oral dose of HRS-1167” NCT06198556 ↗ |
| Target | PARP1 | “PARP1 Inhibitor M9466” NCT06421935 ↗ |